Next Jen: 98% success in testing the merging company – the capital market

After returning from the preservation list this morning and falling by 7%, stock

Next Jen
+ 10.27%

Base:377

opening:390

Tall:450

low:333.1

change:14,207,832

Page Quote News Graphs Company Profile Recommendations


More articles on the subject:




Jumps out following a report that the Saint-Tech company it is in the process of merging, reveals preliminary results showing that the coronary angiography test is 98% accurate after performing hundreds of exhalation biopsies of healthy patients and volunteers.

According to the report, St.-Tech states that after surgery on hundreds of exhalation biopsies from corona patients and healthy volunteers, the identification based on the biomarkers mapped by St.-Tech stands at a sensitivity higher than 91% and a specificity higher than 91.2 In doing so, the company crossed the threshold required for a diagnostic test with efficacy at least equivalent to the ‘gold standard’ test that exists today, which is a PCR test, for the purpose of submitting a regulatory approval to the FDA.

Saint-Tech also reports that it has developed a unique algorithm, which allows for an even higher level of sensitivity and specificity, which at this stage stands at about 98.0% for the identification of the corona virus.

St. Tech reported that after analyzing the chemical composition of hundreds of exhalation biopsies from Corona patients and healthy volunteers (negative PCR), and after analyzing them, both using the company’s unique algorithms and using mathematical models accepted by regulatory authorities in Israel and around the world, the company was able to map several biomarkers. Uniquenesses that enable the identification of Covid-19 patients (corona patients) at different stages of the disease (asymptomatic and symptomatic patients).

The biomarkers identified in the mapping process are a scientific breakthrough and the basis for the construction of a “chemical fingerprint” that will be used to identify corona, corona mutations and immune status, by the company’s commercial system (VOX). The system is currently undergoing a large-scale validation trial at Shamir Hospital (Assaf Harofeh) and which is expected to be completed in about two months. Saint-Tech Medical is preparing to file a patent application for the biomarkers identified by it as soon as possible.

Saint-Tech Medical is developing technologies for the early and rapid detection of diseases in real time, by analyzing the components in the air we exhale using non-invasive, effective and low-cost tests. The technology developed by the company, detects the presence of unique metabolic processes that are related to pathogens or those resulting from the body’s response to pathogens. Each pathogen has a unique genetic expression that creates a metabolic fingerprint, diagnosed by rapid odor test (RST) that identifies various diseases, including diseases Cancer and infections in the early stages, even when the subjects may be asymptomatic.

Next-Jen CEO, Yaniv Hebron: “We are pleased to report results that are a scientific breakthrough that demonstrate the great clinical potential, importance of the development of St. – Tech and the value that it has to bring to Next Jen after the merger. Based on these important results, we are preparing to apply for Ministry of Health approvals. In Israel and the US Food and Drug Administration for the widespread use of technology developed by Saint-Tech around the world.